C atecholaminergic polymorphic ventricular tachycardia (CPVT; Online Mendelian Inheritance in Man [OMIM] , Johns Hopkins University, Baltimore, Md; MIM No. 604772) is a familial arrhythmogenic disorder characterized by adrenergically mediated polymorphic ventricular tachyarrhythmias that lead to syncope and sudden cardiac death. 1, 2 Physical or emotional stress triggers arrhythmias in young individuals, in whom no structural abnormalities of the heart can be observed. Two genetic variants of the disease have been identified, a recessive form caused by homozygous mutations in the calsequestrin-2 (CASQ2) gene, 3 located on chromosome 1, site p13.3-p11 and encoding for the cardiac isoform of calsequestrin, and an autosomal dominant form caused by mutations in the RyR2 gene encoding for the cardiac isoform of the ryanodine receptor 4 on chromosome 1q42.1-q43.
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The cardiac ryanodine receptor (RyR2) is an intracellular Ca 2ϩ release channel located in the membrane of the sarcoplasmic reticulum (SR). 5 Calsequestrin is a high-capacity, low-affinity Ca 2ϩ -binding protein that represents a major Ca 2ϩ -reservoir element within the SR lumen. 6 Both of these Ca 2ϩ -handling proteins are critically involved in cardiac excitation-contraction (EC) coupling through the mechanism of calcium-induced calcium release, 7 thus suggesting that abnormalities in the control of intracellular calcium may represent the central pathogenic pathway in CPVT. Accordingly, it has been speculated that the electrophysiological mechanism for arrhythmias in CPVT is triggered activity initiated by delayed afterdepolarizations (DADs). We recently reported 8 the first functional characterization of the CASQ2 mutant identified by Lahat et al, 3 and we were able to demonstrate that DADs develop as a consequence of a loss of function in calsequestrin, which leads to triggered activity.
As expected for a recessive disease, CASQ2 mutations are less commonly identified in CPVT patients than RyR2 mutations. To date, only 3 homozygous disease-associated sequence variations have been identified in the CASQ2 gene (http://www.fsm.it/cardmoc): a 1-bp deletion, 1 splicing junction mutation, 9 and 1 missense mutation. 3 However, functional characterization is available only for the D307H mutation. 8 Here, we report the identification of 2 new mutations in the CASQ2 gene, and we used the model previously developed 8 to characterize in vitro the mutant peptides and functional derangements of the 2 CASQ2 mutations. Our data have implications for molecular diagnosis of CPVT and for genetic counseling in CPVT families.
Methods

Clinical Evaluation
Two unrelated probands with unexplained syncopal episodes or idiopathic ventricular tachyarrhythmia and 20 family members were referred to our center for clinical and molecular evaluation. Cardiac evaluation included ECG, echocardiogram, exercise stress testing, and Holter recording. Genetic counseling was performed and DNA obtained for genetic analysis. Patients or their guardians provided written informed consent for clinical and genetic evaluation. Protocols were approved by the institutional review board of the Fondazione Salvatore Maugeri.
Genetic Analysis
DNA was extracted from peripheral blood lymphocytes. The coding region of the RyR2 gene was amplified by polymerase chain reaction (PCR) with intronic primers 10 and analyzed by the single-strand conformation polymorphism method. The 11 exons of CASQ2 (GenBank: NM_001232) were amplified with intronic primers and analyzed by denaturing high-performance liquid chromatography (WAVE, Transgenomic, Inc, Omaha, Neb). Abnormal elution profiles were sequenced with a BigDye terminator sequencing kit (Applied Biosystems, Foster City, Calif) and an ABI Prism 310 genetic analyzer(Applied Biosystems) and compared with 600 alleles from healthy subjects with normal ECGs. Haplotype analysis was performed with markers as described 11 previously (Figure 1 ).
Cloning of Human Cardiac Calsequestrin cDNA and Mutagenesis
The full-length coding sequence of human CASQ2 gene was amplified with the Gene Amp XL-PCR kit (Roche, Basel, Switzerland) from DNA pools of a Human Heart cDNA Library Lambda ZAP II Vector (Stratagene, La Jolla, Calif) with Cas1F and Cas11R primers, annealing to the 5Ј-UTR and 3Ј-UTR regions, respectively. The 1.2-kb PCR product was cloned into the pGEM-dT Easy Vector (Promega, Madison, Wis), and the correct sequence was verified by sequencing. Mutations were introduced by site-directed mutagenesis with the QuickChange Mutagenesis Kit (Stratagene) and verified by sequencing.
Recombinant Adenovirus and Gene Transfer
The wild-type (WT) or mutant human CASQ2 cDNA were subcloned in pENTR-4 Vector (Invitrogen Corp, Carlsbad, Calif) and transferred into the Adenoviral Expression pAD/DEST Vector (Invitrogen). Ventricular myocytes were enzymatically dissociated from adult rat hearts, infected with adenoviruses (multiplicity of infection of 100), and maintained in a 5% CO 2 incubator at 37°C. 8 Experiments were performed 48 to 56 hours after infection.
Electrophysiological Recordings
Whole-cell patch-clamp recording of transmembrane ionic currents was performed with an Axopatch 200B amplifier (Axon Instruments, Foster City, Calif). 8 The external solution contained (in mmol/L): 140 NaCl, 5.4 KCl, 1.0 CaCl 2 , 0.5 MgCl 2 , 10 HEPES, and 5.6 glucose, pH 7.3. Micropipettes (borosilicate glass, Sutter Instruments, Novato, Calif; 1-to 3-M⍀ resistance) were filled with the following solution (in mmol/L): 90 cesium aspartate, 50 CsCl, 3 Na 2 ATP, 3.5 MgCl 2 , 10 HEPES, and 0.05 Fluo-3 potassium salt, pH 7.3. Holding potential was Ϫ50 mV; 400-ms voltage pulses were applied at 1-minute intervals from the holding potential to specified membrane potentials. 
Confocal
Western Blot and Stains: All Staining
SDS-PAGE was performed on either 7.5% or 15% gels. 15 Slab gels were stained with the cationic carbocyanine dye "Stains-all" (SigmaAldrich, St Louis, Mo) for identification of Ca 2ϩ -binding proteins. 16 Western blot with anti-CASQ2 polyclonal antibodies (ABR-Affinity Bioreagents, Golden, Colo) was performed as described previously. 17 Levels of CASQ2 in cultured myocytes were determined as described previously. 18 Cell lysate proteins (10 g) were subjected to SDS-PAGE (4% to 20% linear gradient gel), blotted onto nitrocellulose membranes (Bio-Rad Laboratories). Anti-CASQ2 antibodies were used for detection of both rat and human CASQ2 (ABR-Affinity Bioreagents, PAI-913) and for detection of rat CASQ2 (06-382, Upstate, Charlottesville, Va). Blots were quantified with a Visage 2000 Blot Scanning and Analysis system (BioImage Systems Corp).
Calcium Binding
45 Ca ligand overlay was performed on purified CASQ2 (2 to 3 g of protein) electroblotted on nitrocellulose membranes, 19 in a medium containing 5 mmol/L MgSO 4 , 60 mmol/L KCl, 5 mmol/L imidazole, pH 7.4, and 0.6 to 6 mol/L 45 Ca (specific activity 5 to 50 mCi/mg Ca). Single lanes were incubated at room temperature for 20 minutes at different total Ca 2ϩ concentrations ranging from 10 mol/L to 6 mmol/L. After ethanol wash, CASQ2 bands were counted for radioactivity. Background subtraction was obtained by counting an area of nitrocellulose equivalent to that of CASQ2.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Clinical Phenotype
Family I A 6-year-old boy (III-2, Figure 1A ) was referred to our center for the evaluation of effort-induced syncopal episodes since age 3. Physical examination, resting ECG, and echocardiogram were unremarkable, but exercise stress testing demonstrated rapid polymorphic ventricular tachycardia ( Figure  2A ). Holter monitoring showed several runs of asymptomatic polymorphic and bidirectional sustained ventricular tachycardia at rates of 170 to 180 bpm during outdoor playing. The diagnosis of CPVT was established and ␤-blocker treatment initiated. No family history for sudden cardiac death, syncopal events, or effort-or emotion-related arrhythmias was reported. His parents had normal ECGs, and exercise stress testing and Holter monitoring showed no ventricular arrhythmias. They denied consanguinity, as confirmed by haplotype analysis ( Figure 1A ).
Family II
A 17-year-old girl (III-1, Figure 1B ) was referred for evaluation of "idiopathic ventricular arrhythmias." Family history was negative for sudden death, unexplained ventricular tachyarrhythmias, and syncopal events. Parents denied consanguinity. The first manifestation of the disease occurred at age 4, when the child collapsed while playing; the first recorded rhythm at the emergency room was polymorphic ventricular tachycardia at a rate of 200 bpm. Between age 4 and 17 years, the patient experienced multiple syncopal events, and runs of polymorphic ventricular tachycardia were often recorded at Holter monitoring; antiarrhythmic therapy with class I and class III drugs failed to modify the clinical manifestations. When we first saw the patient at age 17 years, both the ECG ( Figure 2B ) and echocardiogram were unremarkable; the diagnosis of CPVT was established, and therapy with ␤-blockers was initiated. After several years of apparent reduction of arrhythmias, sustained runs of ventricular tachycardia were again documented despite compliance with therapy. Electrophysiological studies failed to demonstrate inducibility of ventricular arrhythmias. The patient underwent left cardiac sympathetic denervation that was unable to control cardiac symptoms, and eventually, she received an implantable cardioverter defibrillator.
Genetic Analysis
A homozygous 16-bp deletion in exon 3 (deletion 339 to 354) of CASQ2 was identified in the proband (III-2) of family I ( Figure 1A ). This deletion generates a frame shift that leads to a stop codon 5 amino acids downstream from the deletion site (G112ϩ5X). Evaluation of family members revealed that asymptomatic family members were heterozygous carriers of the deletion, and none of them developed ventricular arrhyth- The proband (III-1) of family II ( Figure 1B ) presented with the same 16-bp deletion in exon 3, previously identified in family I (the 2 families were unrelated, as shown by haplotype analysis in Figure 1 ), on 1 allele and a new missense mutation on the other (L167H). As a consequence, she has no WT cardiac calsequestrin in her cardiac cells. Family screening showed that the proband's mother and the maternal grandfather are asymptomatic heterozygous carriers of the 16-bp deletion, whereas the father and 1 sister (III-3) of the proband are asymptomatic heterozygous carriers of the missense mutation. The other sister (III-2) inherited 2 WT alleles.
Electrophysiological Recordings and Confocal Ca 2؉ Measurements
To characterize the effects of the new CASQ2 mutations on SR Ca 2ϩ handling in vivo, we performed experiments in adult rat ventricular myocytes infected with adenoviral constructs. Virus-mediated expression of human WT and mutant L167H CASQ2 results in an Ϸ2.5-fold increase in the total amount of CASQ2 protein in rat ventricular myocytes 8, 20 (Figure 3) . Importantly, the level of endogenous rat CASQ2 remained unchanged in cells expressing exogenous human CASQ2, as revealed with rat CASQ2-specific antibody (Figure 3 ). Caffeine (10 mmol/L) was applied to myocytes expressing either WT or mutant CASQ2 to evaluate the SR Ca 2ϩ -storing capacity by measurement of fluo-3 fluorescence and of Na ϩ /Ca 2ϩ exchange current (I NCX ; Figure 4A ; G112ϩ5X were much more prominent than those observed with CASQ2
L167H . The effects of the new CASQ2 mutants on the properties of focal fluorescence signals, ie, Ca 2ϩ sparks, were studied in saponin-permeabilized myocytes kept at a constant cytosolic [Ca 2ϩ ] (Ϸ100 nmol/L; Figure 5 ; Table 3 ). When CASQ2 WT was overexpressed, Ca 2ϩ sparks were greater and longer than in native cells, in agreement with our previous results. 20 Compared with WT, expression of CASQ2 G112ϩ5X and of CASQ2 L167H decreased the magnitude of sparks, the spatiotemporal spread of sparks, and the duration of the rising phase of sparks. In agreement with measurements of the global Ca 2ϩ transients, the effects observed with CASQ2 G112ϩ5X were more prominent than those observed with CASQ2
L167H . Finally, we examined the effects of expressing the CASQ2 mutants on Ca 2ϩ transients and action potentials in paced Figure  6 ). Myocytes expressing either the WT or the L167H mutant CASQ2 showed no spontaneous Ca 2ϩ transients or DADs (nϭ4 and nϭ3, respectively; not shown).
Molecular Properties of Mutant CASQ2
To investigate the molecular mechanisms causing aberrant Ca 2ϩ handling in ventricular myocytes, recombinant CASQ2 was expressed in vitro and thereafter purified by standard procedures. All recombinant WT and mutant CASQ2 (CASQ2   WT   , T7-CASQ2   WT   , CASQ2   L167H , and T7-CASQ2 G112ϩ5X ) were found in the soluble fraction after high-speed centrifugation, which indicates that either addition of the T7-Tag, the point mutation (L167H), or the long 260 aa deletion, introduced by G112ϩ5X mutation, did not drastically affect solubility and folding of the relative polypeptides. Western blot experiments showed that all recombinant CASQ2s were recognized by specific anti-CASQ2 polyclonal antibodies. Metachromatically blue staining by Stains-all was preserved for all recombinant CASQ2s except for the deleted form. Recombinant CASQ2
WT without the T7-Tag migrated with a molecular weight of 55 kDa; slower migration was detected for the T7-bearing recombinant protein (T7-CASQ2 WT ), whereas the deleted T7-CASQ2 G112ϩ5X had an estimated molecular weight of Ϸ14 kDa.
Some biochemical properties of native CASQ2 were likewise shared by all recombinant CASQ2s except for T7-CASQ2 G112ϩ5X . In the absence of Ca 2ϩ , successful hydrophobic binding to phenyl-sepharose was obtained; subsequently, quantitative Ca 2ϩ -dependent elution of CASQ2 WT , T7-CASQ2 WT , and CASQ2 L167H showed that the hydrophobic site involved in interaction with phenyl-sepharose (aa 214 to 222) 22 is exposed in the absence of Ca 2ϩ and that 2 to 10 mmol/L Ca 2ϩ induced the expected conformational change that led to internalization of the region, as in native CASQ2.
T7-CASQ2
G112ϩ5X lacked the Ca 2ϩ -regulated hydrophobic site and could not be eluted from phenyl-sepharose. This observation indicates that the hydrophobic/hydrophilic distribution of the residues at the surface of the molecule is sufficient for binding to phenyl-sepharose but does not allow any Ca 2ϩ -dependent conformational change. These results demonstrate that the L167H mutation does not modify the chemical properties of CASQ2, whereas the long deletion drastically affects both the Stains-all-CASQ complex and Ca 2ϩ -induced conformational changes, which indicates that different molecular mechanisms could be involved in the aberrant SR Ca 2ϩ -handling phenotypes. WT were not significantly different (Table 4) .
Calcium Binding to CASQ2
Discussion
Homozygous mutations in the CASQ2 gene cause the recessive form of CPVT, a malignant disease that predisposes young individuals to sudden arrhythmic death. We report the first CPVT patient carrier of 2 heterozygous CASQ2 mutations and a CPVT proband carrier of a new homozygous CASQ2 mutation, and we demonstrate that these mutations impair CASQ2 function. The evidence that carriers of 2 distinct CASQ2 mutations develop CPVT supports the screening of the entire coding region of the CASQ2 gene even in the absence of consanguineous marriage.
Biochemical Properties of the CASQ2 Mutants
Our first objective was to investigate the biochemical properties of CASQ2 G112ϩ5X and of CASQ2 L167H . The CPVT phenotype may be due either to a lowered affinity of CASQ2 for Ca 2ϩ or the inability of mutant CASQ2 to undergo Ca 2ϩ -dependent conformational changes. CASQ2 G112ϩ5X lacks the second, the third, and part of the first domain and is devoid of most of the acidic residues at the COOH-terminal tail, responsible for ion binding 24 ; as predicted, we show that CASQ2 G112ϩ5X has lost its ability to bind Ca 2ϩ . CASQ2 G112ϩ5X also lacks the amino acids involved in either front-to-front or back-to-back interactions, so that its dimerization capability should be compromised. 25, 26 On the other hand, the dibasic hydrophobic site, known to be involved in back-to-back interaction 25, 26 in native CASQ2, is preserved in CASQ2 G112ϩ5X ; thus, we predict that anomalous, stable, Ca 2ϩ -insensitive, pseudohomologous interactions may take place between endogenous CASQ2, CASQ2
WT or CASQ2 L167H , and CASQ2 G112ϩ5X . The functional consequences of the mutant CASQ2 L167H are less predictable. Alignment of the amino acid sequence of CASQ2 from different vertebrates shows that the sequence variation L167H occurs in a highly conserved residue located in a region supposedly involved in heterologous interactions between junctional SR proteins and CASQ2. 27 The hypothesis that the new histidine residue could modify the charge balance of the protein, thus disrupting Ca 2ϩ -binding properties, was not supported by our experiments, ie, no change in Ca 2ϩ -binding properties of CASQ2 L167H was detected. We next asked whether the transition from a hydrophobic amino acid to a basic one could have an impact on Ca 2ϩ -sensitive structural changes of CASQ2, as described for the D307H mutation by Houle et al. 28 However, we showed that CASQ2 L167H had normal solubility and folding properties and displayed the standard Ca 2ϩ -sensitive interaction with phenylsepharose. Thus, CASQ2
L167H responds to Ca 2ϩ with the expected conformational changes, and it does not affect the dimerization capability of CASQ2. We conclude that CASQ2 G112ϩ5X is completely functionally impaired, whereas major biochemical and biophysical properties of CASQ2 L167H are preserved, thus prompting the need for further characterization of electrophysiological properties of myocytes expressing this mutant.
Functional Properties of CASQ2 Mutants in Isolated Adult Cardiac Myocytes
We compared EC coupling and SR Ca 2ϩ handling of the new CASQ2 mutants expressed in ventricular myocytes with those of CASQ2
WT , and we showed that both mutations alter CASQ2 function. Overexpression of the deletion mutant showed dominant-negative effects, as judged by (1) WT , yet no generation of is not a fully functional CASQ2, which suggests that the mutation either influences regulative properties of CASQ2 or retains partial activity and simultaneously acts as a partial dominant negative; these speculations deserve further investigation.
In conclusion, the 2 mutations lead to CASQ2 dysfunction through distinct molecular mechanisms. The inhibitory effects on cellular Ca 2ϩ handling by CASQ2 G112ϩ5X are almost certainly caused by disruption of the CASQ2 polymerization required for high-capacity Ca 2ϩ binding that compromises the Ca 2ϩ sequestration ability of the SR. This is in agreement with the observation that mutants lacking either the N-or C-terminal domains disrupt the "head-to-tail" polymerization of CASQ2. 29, 30 Additionally, in vitro Ca 2ϩ -binding measurements showed a complete lack of Ca 2ϩ binding by CASQ2 G112ϩ5X . Because Ca 2ϩ binding is required for polymerization, these results are also consistent with the notion that mutant monomers cannot form polymers.
As to CASQ2 L167H , its overexpression failed to increase SR Ca 2ϩ content and Ca 2ϩ release compared with CASQ2 WT , thus implying altered regulation of RyR2 Ca 2ϩ release channel function rather than changes in SR Ca 2ϩ capacity. The L167H mutation is localized in the domain that might be involved in heterologous interactions between CASQ2 and the junctional proteins triadin and junctin, 27 which are considered transducers of the CASQ2 effects on RYR2; because CASQ2 modulates RyR2 activity by inhibiting its open probability, defective interactions of CASQ2 with the RyR channel complex could lead to hyperactive RyRs and leaky SR Ca 2ϩ stores. This in turn could contribute to the reduced total SR Ca 2ϩ content in myocytes expressing CASQ2 L167H compared with myocytes overexpressing CASQ2
WT . Future experiments with direct monitoring of intra-SR [Ca 2ϩ ] and measurements of CASQ2-triadin interactions may help to address this possibility.
The cellular mechanisms of CPVT caused by the homozygous G112ϩ5X mutation and by the compound heterozygous G112ϩ5X and L167H mutations appear to be similar to those we previously described for the D307H mutation. 8 
Implications of In Vitro Characterization of CASQ2
G112؉5X and CASQ2
L167H
The experimental investigations reported here raise several interesting points relevant to the understanding of the relationship between CASQ2 mutations and the clinical phenotype. First, we observe that CASQ2 G112ϩ5X is not only unable to perform its physiological task but, when overexpressed in rat myocytes, it also interferes in a "dominant negative" fashion with the endogenous, native CASQ2. The proband of family I is a homozygous carrier of this mutation, and therefore he can be regarded as a CASQ2 "knockout" individual: his clinical phenotype consists of severe ventricular tachyarrhythmias, but he presents no macroscopic (because no biopsy was performed) structural alterations of the myocardium, which suggests that although CASQ2 serves an important role in cardiac cells, its absence is not lethal and does not affect cardiac development in humans. Second, CPVT does not develop in the heterozygous carriers who express either CASQ2
WT or CASQ2 G112ϩ5X ; in fact, none of the 11 heterozygous carriers present in the 2 families developed ventricular arrhythmias. To account for the lack of clinical phenotype in the heterozygous carriers, we may speculate that the CASQ2 G112ϩ5X allele may be translated at a lower level than the WT one, by a nonsense-mediated decay mechanism. 31 
CLINICAL PERSPECTIVE
Homozygous mutations in the cardiac calsequestrin gene (CASQ2) cause the autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease characterized by adrenergically mediated polymorphic and bidirectional ventricular tachycardia and sudden death. We identified a novel homozygous deletion in the calsequestrin gene that led to a stop codon and to a truncated calsequestrin protein in a child with stress-induced ventricular tachycardia and cardiac arrest. The same deletion was also identified in association with a novel point mutation (L167H) in a highly symptomatic CPVT child who was the first CPVT patient carrier of compound heterozygous CASQ2 mutations. In vitro studies demonstrated that both CASQ2 mutants created distinct abnormalities that led to abnormal intracellular calcium regulation, thus facilitating the development of tachyarrhythmias. The first proband, who was homozygous for the deletion that is functionally completely impaired, survived without functional calsequestrin (as if he were a "functional" knockout for the CASQ2) and with no cardiac structural abnormalities. This study shows that carriers of 2 distinct CASQ2 mutations develop CPVT, which indicates that when genetic screening is performed for this disease, the entire coding region of the CASQ2 gene should be screened, even in the absence of consanguinity of the parents of the affected individual.
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